<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453921</url>
  </required_header>
  <id_info>
    <org_study_id>17363</org_study_id>
    <secondary_id>5R01HD047242</secondary_id>
    <nct_id>NCT00453921</nct_id>
  </id_info>
  <brief_title>Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)</brief_title>
  <official_title>Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traumatic brain injury (TBI) is a significant public health problem, with 1.5-2.0 million
      Americans injured each year. Cognitive deficits, particularly in the domains of memory and
      attention are frequently the source of lingering disability after TBI and a source of
      enormous distress to the injured individuals and their family/caregivers. To date,
      interventions to ameliorate chronic cognitive deficits have been directed at either
      pharmacological interventions or cognitive rehabilitation. We propose to (1) To compare the
      efficacy of three interventions: memory and attention training (MAAT), methylphenidate, and
      memory/attention training in combination with methylphenidate and (2) use functional MRI
      (fMRI) to characterize changes in activation of the neural circuitry of memory and attention
      due to MAAT alone, methylphenidate alone, and MAAT in combination with methylphenidate. This
      is a two by two design with medication (methylphenidate/placebo) and cognitive therapy
      (Memory and Attention Training (MAAT) or an Attention control intervention) as possible
      interventions. Using a randomized, placebo-controlled, double-blind design, 200 individuals
      with persistent cognitive deficits 6-12 months after MTBI will be randomized to receive a six
      week trial of either (1) MAAT and placebo, (2) MAAT and methylphenidate (0.3 mg/kg BID), (3)
      attention control intervention and methylphenidate (0.3 mg/kg BID), or (4) attention control
      intervention and placebo. Symptom distress, attention and memory performance, and activation
      patterns of the neural circuitry of attention and memory while undergoing fMRI will be
      characterized at baseline, and after the four treatment conditions. This study will provide
      important information on three interventions for the most disabling sequelae of an enormous
      public health problem. Further, it will help to clarify underlying neural mechanisms and
      suggest additional treatment possibilities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary and Gaps to be Addressed by the Proposed Study

      What is known: There are two interventions of promising efficacy in ameliorating deficits in
      attention and memory after mild traumatic brain injury (MTBI): (i) memory and attention
      training/rehabilitation, and (ii) catecholaminergic augmentation (particularly with
      methylphenidate - which augments both dopaminergic and adrenergic systems). fMRI and other
      functional imaging strategies are providing valuable insights into the underlying neural
      mechanisms of the cognitive enhancing effects of methylphenidate in some neuropsychiatric
      populations (individuals with ADHD), and the effects of cognitive rehabilitation efforts in
      some domains (e.g. speech and language in individuals after stroke).

      What is not known: To date there are no studies that apply a psychopharmacological strategy
      of augmenting neurotransmitter systems known to modulate memory/attention (dopaminergic and
      adrenergic systems) in combination with a cognitive rehabilitation intervention known to
      improve memory/attention (memory/attention training) in individuals with MTBI. We are aware
      of no published studies that use fMRI to assess the neural mechanisms of memory/attention
      improvement from the use of catecholaminergic agents or memory/attention training in
      individuals with MTBI. It is important to determine the efficacy of combined memory/attention
      training and methylphenidate. It is equally important to begin to understand the neural
      mechanisms underlying effective treatment as it may help to inform the development of the
      next generation of interventions and perhaps lead to individually tailored treatment
      interventions. This proposal will start to address these gaps in our knowledge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuropsychological Assessment, CVLT-II</measure>
    <time_frame>post-intervention (at least 7 weeks)</time_frame>
    <description>Memory measure: California Verbal Learning Test, 2nd edition (CVLT), Total, trials 1-5 (range: 0-80). Higher scores are better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropsychological Assessment - CPT, Distractibility Condition (Reaction Time)</measure>
    <time_frame>post-intervention (at least 7 weeks)</time_frame>
    <description>Continuous Performance Test, Distractibility Condition (Reaction Time in msecs) (range: 0-800). Higher score is worse performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional MRI Task Performance and Brain Activation (Change From Baseline to Post-treatment)</measure>
    <time_frame>pre- to post-6 week treatment intervention (at least 7 weeks)</time_frame>
    <description>Change in performance (percent correct,adjusted for guessing) from pre-(baseline) to post-treatment (approximately 7 weeks) for in-scanner n-back working memory task (Range: 0-100). Higher scores means better performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Anterior Cingulate Gyrus Activation During Working Memory Processing (3-back &gt; 0-back Condition) From Baseline to Post-intervention</measure>
    <time_frame>pre- to post-intervention (at least 7 weeks)</time_frame>
    <description>Change from pre- to post-treatment in brain activation in the anterior cingulate region of interest in arbitrary units provided by the SPM (statistical parametric mapping) program (range: unknown). Higher scores indicate greater increase in activation from pre- to post-treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Left Middle/Inferior Frontal Activation During Working Memory Processing (3-back &gt; 0-back Condition) From Baseline to Post-intervention</measure>
    <time_frame>pre- to post-treatment (at least 7 weeks)</time_frame>
    <description>Change from pre- to post-treatment in brain activation in the left middle/inferior frontal region of interest in arbitrary units provided by the SPM (statistical parametric mapping) program (range: unknown). Higher scores indicate greater increase in activation from pre- to post-treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Right Inferior Frontal Activation During Working Memory Processing (3-back &gt; 0-back Condition) From Baseline to Post-intervention</measure>
    <time_frame>pre- to post-treatment (at least 7 weeks)</time_frame>
    <description>Change from pre- to post-treatment in brain activation in the right inferior frontal region of interest in arbitrary units provided by the SPM (statistical parametric mapping) program (range: unknown). Higher scores indicate greater increase in activation from pre- to post-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self Report Questionnaire - MASQ</measure>
    <time_frame>post-intervention (at least 7 weeks)</time_frame>
    <description>The Multiple Abilities Questionnaire (self rating) is a questionnaire in which participants can identify deficits/complaints in the areas of language, visual perception, verbal memory, visual memory and attention and concentration. A total score is calculated; range is 30-130. Higher scores indicate greater level of complaints (worse outcome). For the purposes of this study, a score one standard deviation above the mean (102.7) indicated significant reported cognitive complaints.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Brain Injury</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>Dosage dependent on weight</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Memory and Attention Training</intervention_name>
    <description>Weekly Memory and Attention Training with at home practice.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo as both treatments</intervention_name>
    <description>Placebo capsules and Placebo Memory and Attention Training</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: Individuals aged 18-65 who sustained a mild to severe TBI 4 months prior to study
             entry.

          2. TBI: Subjects must sustain a traumatic blow to the head, resulting in either
             alteration of level of consciousness (manifested by being dazed and confused or having
             amnesia for the event) or loss of consciousness (LOC). Duration of LOC will be
             estimated by using all available information including patient and witness reports,
             emergency personnel records and Dartmouth Hitchcock Medical Center (DHMC) medical
             records. Post traumatic amnesia (PTA) will be estimated by careful questioning of
             patients to determine the time of return of continuous memory. This will be informed
             by review of medical records. We plan to include individuals with intracranial or
             skull injuries stemming from the TBI, providing they meet the inclusion criteria. Such
             lesions will be catalogued, and included as a factor in the data analysis.

          3. Cognitive Deficits: Subjects will have either subjective and objective evidence of
             persistent cognitive deficits. Subjects must report persistent memory or attention
             deficits as a result of their injury, which are of sufficient severity to interfere
             with social and/or occupational functioning. Subjects must either score more than 2
             standard deviations below the age adjusted norm or estimates of baseline premorbid
             function on one or more tests of attention and/or memory administered as part of the
             baseline screening cognitive battery (see below), or score greater than 1.0 standard
             deviations below either age adjusted norms or estimates of premorbid function on 2 or
             more of the screening tests.

        Exclusion Criteria:

        The following factors will exclude otherwise eligible subjects from participation:

          1. a history of other neurologic disorders (such as epilepsy, cerebrovascular disease,
             mental retardation, neurodegenerative disorders)

          2. significant systemic medical illness such as clinically significant liver disease,
             renal disease, atherosclerotic coronary vascular disease, or hypertension requiring
             medication management

          3. current Diagnostic and Statistical Manual (DSM-IV) Axis I diagnosis of psychiatric
             illness other than substance abuse. We have given careful consideration to the
             inclusion of the latter group given our use of a stimulant with potential abuse
             properties. Because of the potential for cross-over abuse with cocaine, amphetamines,
             and other stimulants, individuals with such histories will be excluded from this
             study. Individuals with history of otherwise uncomplicated ethanol or other
             non-stimulant drug abuse currently in stable remission will be eligible. The
             Structured Clinical Interview for DSM-IV (MINI) will be used to screen for psychiatric
             illness

          4. women currently pregnant or lactating. Female participants will be asked to take a
             pregnancy test to confirm they are not currently pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas W McAllister, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center, Dartmouth Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado at Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80291-0238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46266-6057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bianh.org</url>
    <description>Brain Injury Association of New Hampshire</description>
  </link>
  <link>
    <url>http://www.biavt.org/</url>
    <description>Brain Injury Association of Vermont</description>
  </link>
  <reference>
    <citation>McAllister TW, Flashman LA, McDonald BC, Saykin AJ. Mechanisms of working memory dysfunction after mild and moderate TBI: evidence from functional MRI and neurogenetics. J Neurotrauma. 2006 Oct;23(10):1450-67.</citation>
    <PMID>17020482</PMID>
  </reference>
  <reference>
    <citation>Neurobehavioral Guidelines Working Group, Warden DL, Gordon B, McAllister TW, Silver JM, Barth JT, Bruns J, Drake A, Gentry T, Jagoda A, Katz DI, Kraus J, Labbate LA, Ryan LM, Sparling MB, Walters B, Whyte J, Zapata A, Zitnay G. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma. 2006 Oct;23(10):1468-501.</citation>
    <PMID>17020483</PMID>
  </reference>
  <reference>
    <citation>McAllister TW, Rhodes CH, Flashman LA, McDonald BC, Belloni D, Saykin AJ. Effect of the dopamine D2 receptor T allele on response latency after mild traumatic brain injury. Am J Psychiatry. 2005 Sep;162(9):1749-51.</citation>
    <PMID>16135640</PMID>
  </reference>
  <reference>
    <citation>McAllister TW, Flashman LA, Sparling MB, Saykin AJ. Working memory deficits after traumatic brain injury: catecholaminergic mechanisms and prospects for treatment -- a review. Brain Inj. 2004 Apr;18(4):331-50. Review.</citation>
    <PMID>14742148</PMID>
  </reference>
  <reference>
    <citation>McAllister TW, Ferrell RB. Evaluation and treatment of psychosis after traumatic brain injury. NeuroRehabilitation. 2002;17(4):357-68. Review.</citation>
    <PMID>12547983</PMID>
  </reference>
  <reference>
    <citation>Flashman LA, McAllister TW. Lack of awareness and its impact in traumatic brain injury. NeuroRehabilitation. 2002;17(4):285-96. Review.</citation>
    <PMID>12547977</PMID>
  </reference>
  <reference>
    <citation>McAllister TW, Arciniegas D. Evaluation and treatment of postconcussive symptoms. NeuroRehabilitation. 2002;17(4):265-83. Review.</citation>
    <PMID>12547976</PMID>
  </reference>
  <reference>
    <citation>McAllister TW. Evaluation and treatment of neurobehavioral complications of traumatic brain injury--have we made any progress? NeuroRehabilitation. 2002;17(4):263-4.</citation>
    <PMID>12547975</PMID>
  </reference>
  <reference>
    <citation>McAllister TW, Sparling MB, Flashman LA, Saykin AJ. Neuroimaging findings in mild traumatic brain injury. J Clin Exp Neuropsychol. 2001 Dec;23(6):775-91. Review.</citation>
    <PMID>11910544</PMID>
  </reference>
  <reference>
    <citation>McAllister TW, Sparling MB, Flashman LA, Guerin SJ, Mamourian AC, Saykin AJ. Differential working memory load effects after mild traumatic brain injury. Neuroimage. 2001 Nov;14(5):1004-12.</citation>
    <PMID>11697932</PMID>
  </reference>
  <reference>
    <citation>McAllister TW, Saykin AJ, Flashman LA, Sparling MB, Johnson SC, Guerin SJ, Mamourian AC, Weaver JB, Yanofsky N. Brain activation during working memory 1 month after mild traumatic brain injury: a functional MRI study. Neurology. 1999 Oct 12;53(6):1300-8.</citation>
    <PMID>10522888</PMID>
  </reference>
  <reference>
    <citation>McAllister TW. Traumatic Brain Injury and Psychosis: What Is the Connection? Semin Clin Neuropsychiatry. 1998 Jul;3(3):211-223.</citation>
    <PMID>10085209</PMID>
  </reference>
  <reference>
    <citation>Flashman LA, Amador X, McAllister TW. Lack of Awareness of Deficits in Traumatic Brain Injury. Semin Clin Neuropsychiatry. 1998 Jul;3(3):201-210.</citation>
    <PMID>10085208</PMID>
  </reference>
  <reference>
    <citation>McAllister TW, Green RL. Traumatic Brain Injury: A Model of Acquired Psychiatric Illness? Semin Clin Neuropsychiatry. 1998 Jul;3(3):158-159.</citation>
    <PMID>10085203</PMID>
  </reference>
  <reference>
    <citation>McAllister TW. Evaluation of brain injury related behavioral disturbances in community mental health centers. Community Ment Health J. 1997 Aug;33(4):341-58; discussion 359-64. Review.</citation>
    <PMID>9250431</PMID>
  </reference>
  <reference>
    <citation>Silver JM, McAllister TW. Forensic issues in the neuropsychiatric evaluation of the patient with mild traumatic brain injury. J Neuropsychiatry Clin Neurosci. 1997 Winter;9(1):102-13. Review.</citation>
    <PMID>9017537</PMID>
  </reference>
  <reference>
    <citation>McAllister TW. Neuropsychiatric sequelae of head injuries. Psychiatr Clin North Am. 1992 Jun;15(2):395-413. Review.</citation>
    <PMID>1603732</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2007</study_first_posted>
  <results_first_submitted>March 14, 2018</results_first_submitted>
  <results_first_submitted_qc>May 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2018</results_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Laura Flashman</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>TBI</keyword>
  <keyword>Memory</keyword>
  <keyword>Methylphenidate</keyword>
  <keyword>Ritalin</keyword>
  <keyword>Memory and Attention Training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Both Conditions</title>
          <description>Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
Placebo as both treatments: Placebo capsules and Placebo Memory and Attention Training</description>
        </group>
        <group group_id="P2">
          <title>Active Drug/Active Therapy</title>
          <description>Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
Methylphenidate: Dosage dependent on weight
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
        </group>
        <group group_id="P3">
          <title>Active Drug/Placebo Therapy</title>
          <description>Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
Methylphenidate: Dosage dependent on weight</description>
        </group>
        <group group_id="P4">
          <title>Placebo Drug/Active Therapy</title>
          <description>Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Individuals age 18-65 with a traumatic brain injury of at least mild severity at least 4 months prior to study entry, with self-report of cognitive deficits as a result of the injury of sufficient severity to interfere with social and/or occupational functioning.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Both Conditions</title>
          <description>Placebo as both treatments: Placebo capsules and Placebo Memory and Attention Training</description>
        </group>
        <group group_id="B2">
          <title>Active Drug/Active Therapy</title>
          <description>Methylphenidate: Dosage dependent on weight
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
        </group>
        <group group_id="B3">
          <title>Active Drug/Placebo Therapy</title>
          <description>Methylphenidate: Dosage dependent on weight</description>
        </group>
        <group group_id="B4">
          <title>Placebo Drug/Active Therapy</title>
          <description>Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>One participant withdrew from study</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="20"/>
                    <count group_id="B4" value="18"/>
                    <count group_id="B5" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="14.2"/>
                    <measurement group_id="B2" value="43.1" spread="12.3"/>
                    <measurement group_id="B3" value="43.0" spread="15.0"/>
                    <measurement group_id="B4" value="37.2" spread="12.0"/>
                    <measurement group_id="B5" value="40.1" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>One participant withdrew from study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="20"/>
                    <count group_id="B4" value="18"/>
                    <count group_id="B5" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>One participant discontinued participation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="20"/>
                    <count group_id="B4" value="18"/>
                    <count group_id="B5" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>One participant discontinued participation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="20"/>
                    <count group_id="B4" value="18"/>
                    <count group_id="B5" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>One participant discontinued</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="20"/>
                    <count group_id="B4" value="18"/>
                    <count group_id="B5" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Neuropsychological Assessment, CVLT-II</title>
        <description>Memory measure: California Verbal Learning Test, 2nd edition (CVLT), Total, trials 1-5 (range: 0-80). Higher scores are better outcome.</description>
        <time_frame>post-intervention (at least 7 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Both Conditions</title>
            <description>Placebo as both treatments: Placebo capsules and Placebo Memory and Attention Training</description>
          </group>
          <group group_id="O2">
            <title>Active Drug/Active Therapy</title>
            <description>Methylphenidate: Dosage dependent on weight
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
          <group group_id="O3">
            <title>Active Drug/Placebo Therapy</title>
            <description>Methylphenidate: Dosage dependent on weight</description>
          </group>
          <group group_id="O4">
            <title>Placebo Drug/Active Therapy</title>
            <description>Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Assessment, CVLT-II</title>
          <description>Memory measure: California Verbal Learning Test, 2nd edition (CVLT), Total, trials 1-5 (range: 0-80). Higher scores are better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" spread="1.9"/>
                    <measurement group_id="O2" value="51.8" spread="2.1"/>
                    <measurement group_id="O3" value="51.9" spread="1.9"/>
                    <measurement group_id="O4" value="57.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.04</p_value>
            <p_value_desc>For active therapy/placebo relative to both placebo</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Neuropsychological Assessment - CPT, Distractibility Condition (Reaction Time)</title>
        <description>Continuous Performance Test, Distractibility Condition (Reaction Time in msecs) (range: 0-800). Higher score is worse performance.</description>
        <time_frame>post-intervention (at least 7 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Both Conditions</title>
            <description>Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
Placebo as both treatments: Placebo capsules and Placebo Memory and Attention Training</description>
          </group>
          <group group_id="O2">
            <title>Active Drug/Active Therapy</title>
            <description>Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
Methylphenidate: Dosage dependent on weight
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
          <group group_id="O3">
            <title>Active Drug/Placebo Therapy</title>
            <description>Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
Methylphenidate: Dosage dependent on weight</description>
          </group>
          <group group_id="O4">
            <title>Placebo Drug/Active Therapy</title>
            <description>Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Assessment - CPT, Distractibility Condition (Reaction Time)</title>
          <description>Continuous Performance Test, Distractibility Condition (Reaction Time in msecs) (range: 0-800). Higher score is worse performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="426.4" spread="15.3"/>
                    <measurement group_id="O2" value="394.7" spread="17.3"/>
                    <measurement group_id="O3" value="416.6" spread="15.9"/>
                    <measurement group_id="O4" value="413.0" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Functional MRI Task Performance and Brain Activation (Change From Baseline to Post-treatment)</title>
        <description>Change in performance (percent correct,adjusted for guessing) from pre-(baseline) to post-treatment (approximately 7 weeks) for in-scanner n-back working memory task (Range: 0-100). Higher scores means better performance.</description>
        <time_frame>pre- to post-6 week treatment intervention (at least 7 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Both Conditions</title>
            <description>Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
Placebo as both treatments: Placebo capsules and Placebo Memory and Attention Training</description>
          </group>
          <group group_id="O2">
            <title>Active Drug/Active Therapy</title>
            <description>Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
Methylphenidate: Dosage dependent on weight
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
          <group group_id="O3">
            <title>Active Drug/Placebo Therapy</title>
            <description>Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
Methylphenidate: Dosage dependent on weight</description>
          </group>
          <group group_id="O4">
            <title>Placebo Drug/Active Therapy</title>
            <description>Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional MRI Task Performance and Brain Activation (Change From Baseline to Post-treatment)</title>
          <description>Change in performance (percent correct,adjusted for guessing) from pre-(baseline) to post-treatment (approximately 7 weeks) for in-scanner n-back working memory task (Range: 0-100). Higher scores means better performance.</description>
          <units>percentage of correct targets (adjusted)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.46" spread="30.8"/>
                    <measurement group_id="O2" value="4.69" spread="26.8"/>
                    <measurement group_id="O3" value="4.86" spread="29.5"/>
                    <measurement group_id="O4" value="-0.36" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Looking for statistical difference, p &lt; .01, between groups looking at change scores</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Anterior Cingulate Gyrus Activation During Working Memory Processing (3-back &gt; 0-back Condition) From Baseline to Post-intervention</title>
        <description>Change from pre- to post-treatment in brain activation in the anterior cingulate region of interest in arbitrary units provided by the SPM (statistical parametric mapping) program (range: unknown). Higher scores indicate greater increase in activation from pre- to post-treatment.</description>
        <time_frame>pre- to post-intervention (at least 7 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Both Conditions</title>
            <description>Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
Placebo as both treatments: Placebo capsules and Placebo Memory and Attention Training</description>
          </group>
          <group group_id="O2">
            <title>Active Drug/Active Therapy</title>
            <description>Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
Methylphenidate: Dosage dependent on weight
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
          <group group_id="O3">
            <title>Active Drug/Placebo Therapy</title>
            <description>Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
Methylphenidate: Dosage dependent on weight</description>
          </group>
          <group group_id="O4">
            <title>Placebo Drug/Active Therapy</title>
            <description>Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Anterior Cingulate Gyrus Activation During Working Memory Processing (3-back &gt; 0-back Condition) From Baseline to Post-intervention</title>
          <description>Change from pre- to post-treatment in brain activation in the anterior cingulate region of interest in arbitrary units provided by the SPM (statistical parametric mapping) program (range: unknown). Higher scores indicate greater increase in activation from pre- to post-treatment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread=".36"/>
                    <measurement group_id="O2" value="0.09" spread=".36"/>
                    <measurement group_id="O3" value="0.20" spread=".42"/>
                    <measurement group_id="O4" value="0.05" spread=".27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>group differences</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Left Middle/Inferior Frontal Activation During Working Memory Processing (3-back &gt; 0-back Condition) From Baseline to Post-intervention</title>
        <description>Change from pre- to post-treatment in brain activation in the left middle/inferior frontal region of interest in arbitrary units provided by the SPM (statistical parametric mapping) program (range: unknown). Higher scores indicate greater increase in activation from pre- to post-treatment.</description>
        <time_frame>pre- to post-treatment (at least 7 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Both Conditions</title>
            <description>Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
Placebo as both treatments: Placebo capsules and Placebo Memory and Attention Training</description>
          </group>
          <group group_id="O2">
            <title>Active Drug/Active Therapy</title>
            <description>Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
Methylphenidate: Dosage dependent on weight
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
          <group group_id="O3">
            <title>Active Drug/Placebo Therapy</title>
            <description>Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
Methylphenidate: Dosage dependent on weight</description>
          </group>
          <group group_id="O4">
            <title>Placebo Drug/Active Therapy</title>
            <description>Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Middle/Inferior Frontal Activation During Working Memory Processing (3-back &gt; 0-back Condition) From Baseline to Post-intervention</title>
          <description>Change from pre- to post-treatment in brain activation in the left middle/inferior frontal region of interest in arbitrary units provided by the SPM (statistical parametric mapping) program (range: unknown). Higher scores indicate greater increase in activation from pre- to post-treatment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread=".20"/>
                    <measurement group_id="O2" value="0.04" spread=".15"/>
                    <measurement group_id="O3" value="0.07" spread=".24"/>
                    <measurement group_id="O4" value=".10" spread=".21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Right Inferior Frontal Activation During Working Memory Processing (3-back &gt; 0-back Condition) From Baseline to Post-intervention</title>
        <description>Change from pre- to post-treatment in brain activation in the right inferior frontal region of interest in arbitrary units provided by the SPM (statistical parametric mapping) program (range: unknown). Higher scores indicate greater increase in activation from pre- to post-treatment.</description>
        <time_frame>pre- to post-treatment (at least 7 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Both Conditions</title>
            <description>Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
Placebo as both treatments: Placebo capsules and Placebo Memory and Attention Training</description>
          </group>
          <group group_id="O2">
            <title>Active Drug/Active Therapy</title>
            <description>Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
Methylphenidate: Dosage dependent on weight
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
          <group group_id="O3">
            <title>Active Drug/Placebo Therapy</title>
            <description>Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
Methylphenidate: Dosage dependent on weight</description>
          </group>
          <group group_id="O4">
            <title>Placebo Drug/Active Therapy</title>
            <description>Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Right Inferior Frontal Activation During Working Memory Processing (3-back &gt; 0-back Condition) From Baseline to Post-intervention</title>
          <description>Change from pre- to post-treatment in brain activation in the right inferior frontal region of interest in arbitrary units provided by the SPM (statistical parametric mapping) program (range: unknown). Higher scores indicate greater increase in activation from pre- to post-treatment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread=".28"/>
                    <measurement group_id="O2" value="0.05" spread=".28"/>
                    <measurement group_id="O3" value=".15" spread=".29"/>
                    <measurement group_id="O4" value=".14" spread=".22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self Report Questionnaire - MASQ</title>
        <description>The Multiple Abilities Questionnaire (self rating) is a questionnaire in which participants can identify deficits/complaints in the areas of language, visual perception, verbal memory, visual memory and attention and concentration. A total score is calculated; range is 30-130. Higher scores indicate greater level of complaints (worse outcome). For the purposes of this study, a score one standard deviation above the mean (102.7) indicated significant reported cognitive complaints.</description>
        <time_frame>post-intervention (at least 7 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Both Conditions</title>
            <description>Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
Placebo as both treatments: Placebo capsules and Placebo Memory and Attention Training</description>
          </group>
          <group group_id="O2">
            <title>Active Drug/Active Therapy</title>
            <description>Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
Methylphenidate: Dosage dependent on weight
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
          <group group_id="O3">
            <title>Active Drug/Placebo Therapy</title>
            <description>Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
Methylphenidate: Dosage dependent on weight</description>
          </group>
          <group group_id="O4">
            <title>Placebo Drug/Active Therapy</title>
            <description>Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Self Report Questionnaire - MASQ</title>
          <description>The Multiple Abilities Questionnaire (self rating) is a questionnaire in which participants can identify deficits/complaints in the areas of language, visual perception, verbal memory, visual memory and attention and concentration. A total score is calculated; range is 30-130. Higher scores indicate greater level of complaints (worse outcome). For the purposes of this study, a score one standard deviation above the mean (102.7) indicated significant reported cognitive complaints.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.4" spread="4.5"/>
                    <measurement group_id="O2" value="120.5" spread="4.8"/>
                    <measurement group_id="O3" value="114.1" spread="4.5"/>
                    <measurement group_id="O4" value="118.1" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>a priopr</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years</time_frame>
      <desc>Physical Symptom Checklist was completed at each visit and phone call.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Both Conditions</title>
          <description>Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
Placebo as both treatments: Placebo capsules and Placebo Memory and Attention Training</description>
        </group>
        <group group_id="E2">
          <title>Active Med/Active Therapy</title>
          <description>Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
Methylphenidate: Dosage dependent on weight
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
        </group>
        <group group_id="E3">
          <title>Active Med/Placebo Therapy</title>
          <description>Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
Methylphenidate: Dosage dependent on weight</description>
        </group>
        <group group_id="E4">
          <title>Placebo Med/Active Therapy</title>
          <description>Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
Memory and Attention Training: Weekly Memory and Attention Training with at home practice.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="18" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E3" events="14" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>loss of appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="30" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E3" events="18" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E3" events="11" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" events="8" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="20" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E3" events="16" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="14" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="20" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E3" events="15" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="18" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E3" events="14" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" events="8" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Laura Flashman</name_or_title>
      <organization>Dartmouth Hitchcock Medical Center</organization>
      <phone>6036505824</phone>
      <email>Laura.A.Flashman@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

